ArticleBlood. Red cells & iron2025

crizanlizumab and inclacumab are equally potent inhibitors of cell adhesion in the blood of patients with sickle cell disease.

Tina Rubic-Schneider et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.